创新药概念震荡反弹高增长潜力概念股出炉_老虎社区_美港股上老虎

创新药概念震荡反弹高增长潜力概念股出炉

腾讯自选股综合02-10

创新药概念盘中震荡反弹，广生堂涨超10%，此前万邦德涨停，尖峰集团、信立泰、北陆药业、荣昌生物、首药控股等多股涨超5%。消息面上，2025年中国创新药License-out总交易规模达到创纪录的1357亿美元，2026年开年以来重磅合作频出，除信达外，1月份石药-阿斯利康（185亿美元）、荣昌-艾伯维（56亿美元）两笔超级BD均充分验证国产创新药管线的全球价值。需要注意的是，2月9日，1-8批国家...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2610969486?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-10 11:17","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2610969486","market":"hk","top_or_hot":-1,"title":"创新药概念震荡反弹 高增长潜力概念股出炉","media":"腾讯自选股综合","content":"<div>\n<p>创新药概念盘中震荡反弹，广生堂涨超10%，此前万邦德涨停，尖峰集团、信立泰、北陆药业、荣昌生物、首药控股等多股涨超5%。消息面上，2025年中国创新药License-out总交易规模达到创纪录的1357亿美元，2026年开年以来重磅合作频出，除信达外，1月份石药-阿斯利康（185亿美元）、荣昌-艾伯维（56亿美元）两笔超级BD均充分验证国产创新药管线的全球价值。需要注意的是，2月9日，1-8批国家...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>创新药概念震荡反弹 高增长潜力概念股出炉</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n创新药概念震荡反弹 高增长潜力概念股出炉\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-10 11:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b><strong>腾讯自选股综合</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>创新药概念盘中震荡反弹，广生堂涨超10%，此前万邦德涨停，尖峰集团、信立泰、北陆药业、荣昌生物、首药控股等多股涨超5%。消息面上，2025年中国创新药License-out总交易规模达到创纪录的1357亿美元，2026年开年以来重磅合作频出，除信达外，1月份石药-阿斯利康（185亿美元）、荣昌-艾伯维（56亿美元）两笔超级BD均充分验证国产创新药管线的全球价值。需要注意的是，2月9日，1-8批国家...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"丽珠医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","article_id":"2610969486","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610969486","pubTimestamp":1770693474,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"创新药概念盘中震荡反弹，广生堂涨超10%，此前万邦德涨停，尖峰集团、信立泰、北陆药业、荣昌生物、首药控股等多股涨超5%。华源证券指出，经历短期波动消化后，创新药板块已显现企稳回暖迹象。整体上，国金证券认为创新药前期回调较为充分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。从未来增长潜力来看，多股获机构预测2026年净利增速有望翻倍。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01513":"丽珠医药","00867":"康哲药业","01276":"恒瑞医药","BK1515":"抗疫概念","BK1574":"生物医药B类股","00013":"和黄医药","BK1583":"高瓴概念","00512":"远大医药","06185":"康希诺生物","01952":"云顶新耀","02269":"药明生物","02228":"晶泰控股","01093":"石药集团","01801":"信达生物","02196":"复星医药","02096":"先声药业","06978":"永泰生物-B","01177":"中国生物制药","03692":"翰森制药","01548":"金斯瑞生物科技","BK1161":"生物科技","06160":"百济神州","01877":"君实生物"},"translate_title":"The concept of innovative drugs fluctuates and rebounds, concept stocks with high growth potential are released","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":0.9,"02196":0.9,"01548":0.9,"06978":1.5,"01513":0.9,"00512":0.9,"01801":0.9,"01877":0.9,"06160":0.9,"06185":0.9,"03692":0.9,"00867":0.9,"01276":0.9,"02096":0.9,"00013":0.9,"02269":0.9,"01952":0.9,"02228":0.9,"01177":0.9},"content_text":"创新药概念盘中震荡反弹，广生堂涨超10%，此前万邦德涨停，尖峰集团、信立泰、北陆药业、荣昌生物、首药控股等多股涨超5%。消息面上，2025年中国创新药License-out总交易规模达到创纪录的1357亿美元，2026年开年以来重磅合作频出，除信达外，1月份石药-阿斯利康（185亿美元）、荣昌-艾伯维（56亿美元）两笔超级BD均充分验证国产创新药管线的全球价值。需要注意的是，2月9日，1-8批国家集采药品新一轮接续采购开标产生拟中选结果。本次接续采购涉及1-8批国家集采的316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、呼吸系统、消化系统等26个治疗领域。本次集采中选预期更加明确，鲜明体现“反内卷”导向。华源证券指出，经历短期波动消化后，创新药板块已显现企稳回暖迹象。我们建议精选基本面强劲、前期调整充分的创新药个股，看好未来股价有望走出新高度，同时建议积极关注医疗新科技等板块，以及26年困境反转的底部个股。创新药建议关注，恒瑞医药、信立泰、泽璟制药、热景生物、科伦药业、上海谊众、康弘药业、华纳药厂、前沿生物、福元医药、苑东生物、昂利康。国金证券则指出，短期来看，2-3月有望迎来创新药企业的业绩披露窗口，多家药企有望迎来减亏或扭亏，同时我们预计2026年更多创新药企业有望扭亏并大幅释放利润。展望全年，AACR（4月）、ASCO（5月）、ESMO（10月）等学术会议上国产创新药有望进一步带来临床数据的兑现。整体上，国金证券认为创新药前期回调较为充分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。从未来增长潜力来看，多股获机构预测2026年净利增速有望翻倍。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}